# A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism

> **NCT05187377** · PHASE2 · COMPLETED · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 32 (actual)

## Conditions studied

- Phelan-McDermid Syndrome
- Autism Spectrum Disorder (ASD)

## Interventions

- **DRUG:** Growth Hormone
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT05187377
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-19
- **Primary completion:** 2025-01-28
- **Final completion:** 2025-02-05
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05187377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05187377, "A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05187377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*